Citations Report
Clinical Schizophrenia & Related Psychoses : Citations & Metrics Report
Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.
Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total published articles |
105 | 141 | 28 | 8 | 28 |
Conference proceedings |
0 | 0 | 0 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
543 | 553 | 590 | 563 | 587 |
Journal total citations count | 6601 |
Journal impact factor | 6.49 |
Journal 5 years impact factor | 12.17 |
Journal cite score | 11.19 |
Journal h-index | 41 |
Journal h-index since 2019 | 26 |
Raja, Michele. "Clozapine safety, 35 years later." Current drug safety 6, no. 3 (2011): 164-184. |
|
Gitrome, Leslie. "Schizophrenia: what can we do about it?." Current Psychiatry 10, no. 6 (2011): 52-60. |
|
Nooijen, Patty MM, Felix Carvalho, and Robert J. Flanagan. "Haematological toxicity of clozapine and some other drugs used in psychiatry." Human Psychopharmacology: Clinical and Experimental 26, no. 2 (2011): 112-119. |
|
Nielsen, Jimmi, Christoph U. Correll, Peter Manu, and John M. Kane. "Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?." The Journal of clinical psychiatry 74, no. 6 (2013): 0-0. |
|
Yüksel, Rabia Nazik, Di?dem Göverti, Aybeniz Civan Kahve, I??k Batuhan Çakmak, Çi?dem Yücel, and Erol Göka. "Galectin-1 and galectin-3 levels in patients with schizophrenia and their unaffected siblings." Psychiatric Quarterly 91, no. 3 (2020): 715-725. |
|
Kantrowitz, Joshua T. "Targeting Serotonin 5-HT 2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches." CNS drugs (2020): 1-13. |
|
Bodatsch, Mitja, Joachim Klosterkötter, and Jörg Daumann. "Contributions of experimental psychiatry to research on the psychosis prodrome." Frontiers in psychiatry 4 (2013): 170. |
|
Roberts, Rosalinda C., Joy K. Roche, Shahza M. Somerville, and Robert R. Conley. "Ultrastructural distinctions between treatment responders and non-responders in schizophrenia: postmortem studies of the striatum." Mental Illness/Book 2 (2012): 261-286. |
|
Kowalec, Kaarina, Yi Lu, Jie Song, Christina Dalman, Christina M. Hultman, Henrik Larsson, Paul Lichtenstein, and Patrick F. Sullivan. "The association between family history and genomic burden with schizophrenia mortality: a Swedish population-based register and genetic sample study." Translational psychiatry 11, no. 1 (2021): 1-9. |
|
Walker, Ashley E., Jerrod D. Spring, and Michael J. Travis. "Addressing cognitive deficits in schizophrenia: Toward a neurobiologically informed approach." Biological psychiatry 81, no. 1 (2017): e1-e3. |
|
Mosley, Jacqueline C. "The Economic Burden of Comorbid Serious Mental Illness and Chronic Non-communicable Disease in Working Age Adults in the United States." PhD diss., Tulane University, School of Public Health and Tropical Medicine, 2015. |
|
Citrome, Leslie. "Treatment-refractory schizophrenia: what is it and what has been done about it?." Neuropsychiatry 1, no. 4 (2011): 325. |
|
Stelzhammer, Viktoria, Bob Amess, Daniel Martins?de?Souza, Yishai Levin, Susan E. Ozanne, Malgorzata S. Martin?Gronert, Sebastian Urday, Sabine Bahn, and Paul C. Guest. "Analysis of the rat hypothalamus proteome by data?independent label?free LC?MS/MS." Proteomics 12, no. 22 (2012): 3386-3392. |
|
Buckley, Peter F., and Brian J. Miller. "Rheumatoid Arthritis Drugs for Schizophrenia?." Psychiatric Annals 48, no. 5 (2018): 232-236. |
|
Ethridge, Lauren, Stephan Moratti, Yuan Gao, Andreas Keil, and Brett A. Clementz. "Sustained versus transient brain responses in schizophrenia: the role of intrinsic neural activity." Schizophrenia research 133, no. 1-3 (2011): 106-111. |
|
Krzystanek, Marek, and Artur Pa?asz. "NMDA receptor model of antipsychotic drug-induced hypofrontality." International journal of molecular sciences 20, no. 6 (2019): 1442. |
|
Sapkota, Kiran, Mark W. Irvine, Guangyu Fang, Erica S. Burnell, Neil Bannister, Arturas Volianskis, Georgia R. Culley et al. "Mechanism and properties of positive allosteric modulation of N-methyl-D-aspartate receptors by 6-alkyl 2-naphthoic acid derivatives." Neuropharmacology 125 (2017): 64-79. |
|
Muscatello, Maria Rosaria A., Antonio Bruno, Pasquale De Fazio, Cristina Segura-Garcia, Gianluca Pandolfo, and Rocco Zoccali. "Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine." Expert opinion on pharmacotherapy 15, no. 16 (2014): 2329-2345. |
|
Leppik, Liisa, Madis Parksepp, Sven Janno, Kati Koido, Liina Haring, Eero Vasar, and Mihkel Zilmer. "Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis." European archives of psychiatry and clinical neuroscience 270, no. 1 (2020): 59-70. |
|
Kantrowitz, Joshua T., and Leslie Citrome. "Lurasidone for schizophrenia: what’s different?." Expert review of neurotherapeutics 12, no. 3 (2012): 265-273. |
|